<!DOCTYPE html><html lang="en"><head><meta charset="UTF-8"><meta name="viewport" content="width=device-width,initial-scale=1.0"><title>Eye Health — SugarWise</title><link rel="stylesheet" href="styles.css">
    <link rel="icon" type="image/svg+xml" href="favicon.svg"><meta property="og:type" content="website"><meta property="og:site_name" content="SugarWise"><meta property="og:url" content="https://aravindcleaerr.github.io/diabetes-guide/eye-health.html"><meta property="og:description" content="Free educational diabetes management guide. Not medical advice."></head><body>
    <a href="#main" class="skip-link">Skip to content</a>
<nav class="navbar"><div class="navbar-inner"><a class="brand" href="index.html">SugarWise</a><a class="home-link" href="index.html">All Topics</a></div></nav>
<div class="container" id="main" role="main">
<div class="page-header"><h1>Eye Health &amp; Diabetic Retinopathy</h1><p>Diabetic eye disease is a leading cause of blindness in working-age adults. Regular screening and timely treatment can prevent over 90% of severe vision loss.</p></div>
<div class="last-reviewed">Content last reviewed: January 2026 | AI-assisted content</div>

<div class="illus">
<svg width="180" height="120" viewBox="0 0 180 120" fill="none" xmlns="http://www.w3.org/2000/svg">
<!-- eye outline -->
<path d="M10 60 Q90 0 170 60 Q90 120 10 60Z" fill="#e6f5ef" stroke="#1a7a5a" stroke-width="2.5"/>
<!-- iris -->
<circle cx="90" cy="60" r="28" fill="#3182ce" opacity="0.8"/>
<!-- pupil -->
<circle cx="90" cy="60" r="12" fill="#1a202c">
<animate attributeName="r" values="12;9;12" dur="3s" repeatCount="indefinite"/>
</circle>
<!-- light reflection -->
<circle cx="82" cy="52" r="5" fill="#fff" opacity="0.7"/>
<circle cx="96" cy="66" r="2.5" fill="#fff" opacity="0.4"/>
<!-- scan line -->
<line x1="10" y1="60" x2="170" y2="60" stroke="#1a7a5a" stroke-width="1" opacity="0.3" stroke-dasharray="4 4">
<animate attributeName="y1" values="45;75;45" dur="4s" repeatCount="indefinite"/>
<animate attributeName="y2" values="45;75;45" dur="4s" repeatCount="indefinite"/>
</line>
</svg>
</div>

<div class="section">
<h2><span class="icon-sm">&#128065;</span> Overview of Diabetic Eye Disease</h2>
<p>Diabetes affects the eyes in multiple ways. The retina — the light-sensitive tissue lining the back of the eye — is particularly vulnerable because its tiny blood vessels are directly damaged by chronic hyperglycemia. Diabetic retinopathy is the most common and most sight-threatening complication, but diabetes also increases the risk of cataracts, glaucoma, and other ocular conditions.</p>
<ul>
<li>After 20 years of diabetes, nearly all people with Type 1 and over 60% with Type 2 have some degree of retinopathy.</li>
<li>Diabetic retinopathy is the leading cause of new cases of blindness in adults aged 20-74.</li>
<li>Vision loss from diabetic retinopathy is largely preventable with early detection and treatment.</li>
</ul>
</div>

<div class="section">
<h2><span class="icon-sm">&#128200;</span> Stages of Diabetic Retinopathy</h2>
<h3>Non-Proliferative Diabetic Retinopathy (NPDR)</h3>
<p>The early stage, where damaged blood vessels leak fluid, lipids, and blood into the retina.</p>
<div class="table-wrap">
<table>
<thead>
<tr><th>Severity</th><th>Findings</th><th>Risk of Progression</th></tr>
</thead>
<tbody>
<tr><td>Mild NPDR</td><td>At least one microaneurysm</td><td>Low — 5% progress to PDR in 1 year</td></tr>
<tr><td>Moderate NPDR</td><td>Microaneurysms, dot-blot hemorrhages, hard exudates, cotton-wool spots</td><td>Moderate — 12-27% progress to PDR in 1 year</td></tr>
<tr><td>Severe NPDR</td><td>Extensive hemorrhages in all 4 quadrants, venous beading in 2+ quadrants, or IRMA in 1+ quadrant (4-2-1 rule)</td><td>High — 52% progress to PDR in 1 year</td></tr>
</tbody>
</table>
</div>

<h3>Proliferative Diabetic Retinopathy (PDR)</h3>
<p>The advanced stage, driven by retinal ischemia. The retina releases vascular endothelial growth factor (VEGF), which stimulates the growth of new, fragile blood vessels (neovascularization). These abnormal vessels can bleed into the vitreous cavity (vitreous hemorrhage) or cause tractional retinal detachment, both of which can cause sudden severe vision loss.</p>
<ul>
<li>Neovascularization of the disc (NVD) or elsewhere (NVE).</li>
<li>Vitreous or preretinal hemorrhage.</li>
<li>Fibrous tissue formation and tractional retinal detachment.</li>
<li>Neovascular glaucoma (new vessels block aqueous drainage).</li>
</ul>
<div class="timeline">
<div class="timeline-item"><div class="timeline-title">Mild NPDR</div><div class="timeline-text">Microaneurysms only; low progression risk (~5%/yr)</div></div>
<div class="timeline-item"><div class="timeline-title">Moderate NPDR</div><div class="timeline-text">Hemorrhages, exudates, cotton-wool spots; moderate risk (12-27%/yr)</div></div>
<div class="timeline-item"><div class="timeline-title">Severe NPDR</div><div class="timeline-text">Extensive changes in all quadrants (4-2-1 rule); high risk (52%/yr)</div></div>
<div class="timeline-item"><div class="timeline-title">Proliferative DR</div><div class="timeline-text">New fragile vessels grow; risk of vitreous hemorrhage and detachment</div></div>
<div class="timeline-item"><div class="timeline-title">DME (any stage)</div><div class="timeline-text">Fluid leaks into macula; most common cause of vision loss</div></div>
</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#128167;</span> Diabetic Macular Edema (DME)</h2>
<p>Diabetic macular edema can occur at any stage of retinopathy and is the most common cause of vision loss in diabetic eye disease. It results from leakage of fluid and lipoproteins from damaged capillaries into the macula (the central part of the retina responsible for sharp vision).</p>
<ul>
<li>Symptoms: blurred central vision, difficulty reading, distorted vision, faded colors.</li>
<li>Diagnosed by optical coherence tomography (OCT), which measures retinal thickness.</li>
<li>Classified as center-involving (worse prognosis) or non-center-involving.</li>
</ul>
</div>

<div class="section">
<h2><span class="icon-sm">&#128083;</span> Other Diabetic Eye Conditions</h2>
<h3>Cataracts</h3>
<ul>
<li>People with diabetes develop cataracts at a younger age and they progress faster.</li>
<li>Sorbitol accumulation in the lens (via the polyol pathway) causes osmotic swelling and opacification.</li>
<li>Treatment: surgical lens replacement when vision is significantly affected.</li>
</ul>
<h3>Glaucoma</h3>
<ul>
<li>Open-angle glaucoma is 1.4 times more common in people with diabetes.</li>
<li>Neovascular glaucoma can develop in advanced PDR — a sight-threatening emergency.</li>
<li>Screening includes intraocular pressure measurement and optic nerve assessment.</li>
</ul>
</div>

<div class="section">
<h2><span class="icon-sm">&#128197;</span> Screening Recommendations</h2>
<div class="table-wrap">
<table>
<thead>
<tr><th>Diabetes Type</th><th>When to Start</th><th>Frequency</th></tr>
</thead>
<tbody>
<tr><td>Type 1</td><td>Within 5 years of diagnosis</td><td>Annually (can extend to every 2 years if no retinopathy on multiple exams)</td></tr>
<tr><td>Type 2</td><td>At the time of diagnosis</td><td>Annually (can extend to every 2 years if no retinopathy)</td></tr>
<tr><td>Pregnancy (pre-existing diabetes)</td><td>Before conception or in the first trimester</td><td>Every trimester; up to 1 year postpartum</td></tr>
</tbody>
</table>
</div>
<ul>
<li><strong>Dilated fundus examination</strong> by an ophthalmologist or optometrist trained in diabetic eye disease is the gold standard.</li>
<li><strong>Retinal photography</strong> (fundus camera) with remote reading is an acceptable alternative, especially for screening in primary care or remote settings.</li>
<li><strong>OCT</strong> is used to assess macular edema and guide treatment decisions.</li>
<li><strong>Fluorescein angiography</strong> may be used to map areas of ischemia and leakage before laser treatment.</li>
</ul>
<div class="note">Retinopathy can be asymptomatic until very late stages. You cannot rely on "good vision" to rule out disease. Annual eye exams are non-negotiable.</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#128137;</span> Treatment</h2>
<h3>Anti-VEGF Injections</h3>
<ul>
<li>First-line treatment for center-involving DME and often for PDR.</li>
<li>Agents: ranibizumab (Lucentis), aflibercept (Eylea), bevacizumab (Avastin — off-label but widely used), faricimab (Vabysmo).</li>
<li>Injected directly into the vitreous cavity (intravitreal injection) — sounds frightening but is quick and well-tolerated with topical anesthesia.</li>
<li>Typically requires multiple injections initially (monthly for 3-6 months), then as needed based on response.</li>
<li>Highly effective: most patients stabilize or improve vision.</li>
</ul>
<h3>Laser Photocoagulation</h3>
<ul>
<li><strong>Panretinal photocoagulation (PRP):</strong> For PDR — hundreds of laser burns are applied to the peripheral retina to reduce VEGF production and cause regression of new vessels. Can cause some peripheral vision and night vision loss.</li>
<li><strong>Focal/grid laser:</strong> For non-center-involving DME — targeted laser to leaking microaneurysms.</li>
<li>Laser remains important as a durable treatment option, especially when anti-VEGF access is limited or follow-up is unreliable.</li>
</ul>
<h3>Vitrectomy</h3>
<ul>
<li>Surgical removal of vitreous gel — indicated for non-clearing vitreous hemorrhage, tractional retinal detachment involving the macula, or combined tractional-rhegmatogenous detachment.</li>
<li>Modern vitrectomy (25/27-gauge) is minimally invasive with good recovery.</li>
</ul>
<h3>Intravitreal Corticosteroids</h3>
<ul>
<li>Dexamethasone implant (Ozurdex) or fluocinolone acetonide implant (Iluvien) for DME unresponsive to anti-VEGF therapy.</li>
<li>Risk of cataract progression and elevated intraocular pressure.</li>
</ul>
</div>

<div class="section">
<h2><span class="icon-sm">&#128737;</span> Prevention Through Systemic Control</h2>
<ul>
<li><strong>Glucose control:</strong> Every 1% reduction in HbA1c reduces retinopathy risk by ~30-40% (DCCT/UKPDS).</li>
<li><strong>Blood pressure control:</strong> Hypertension accelerates retinopathy progression. Target &lt;130/80 mmHg.</li>
<li><strong>Lipid control:</strong> Fenofibrate has shown benefit in reducing retinopathy progression in some trials (FIELD, ACCORD-Eye), independent of lipid levels.</li>
<li><strong>Avoid rapid glucose correction:</strong> Very rapid HbA1c lowering (especially from very high levels) can paradoxically worsen retinopathy transiently ("early worsening"). Gradual improvement over months is safer.</li>
<li><strong>Smoking cessation:</strong> Smoking impairs retinal blood flow and worsens outcomes.</li>
</ul>
</div>

<div class="section">
<h2><span class="icon-sm">&#128680;</span> When to See an Ophthalmologist Urgently</h2>
<div class="warning">Seek immediate ophthalmic evaluation if you experience any of the following:
<ul>
<li>Sudden loss of vision in one or both eyes</li>
<li>Sudden shower of floaters (spots, cobwebs) — may indicate vitreous hemorrhage</li>
<li>Flashing lights — may indicate retinal traction or detachment</li>
<li>A shadow or curtain across part of your vision — may indicate retinal detachment</li>
<li>Sudden eye pain or redness with vision loss — may indicate neovascular glaucoma</li>
</ul>
These symptoms can represent sight-threatening emergencies that require same-day evaluation.</div>
</div>

<div class="section see-also"><h3>Related Topics</h3><ul>
<li><a href="blood-sugar-monitoring.html">Blood Sugar Monitoring</a></li>
<li><a href="complications-overview.html">Complications Overview</a></li>
</ul></div>
<div class="page-nav">
<a class="prev" href="kidney-health.html">Kidney Health</a>
<a class="next" href="nerve-damage.html">Nerve Damage</a>
</div>
</div>
<div class="disclaimer">This content is for educational purposes only and does not replace professional medical advice. The creators of SugarWise are not medical professionals. Do not start, stop, or change any medication without consulting your doctor. In case of emergency, call 112 (India) or your local emergency number. <a href="terms-of-use.html">Read full Terms of Use &amp; Medical Disclaimer</a></div>
<div class="privacy-notice">SugarWise does not use cookies, collect personal data, or track users.</div>
<div class="footer"><span class="ai-badge">AI-Assisted Content</span><br>SugarWise &bull; Comprehensive Diabetes Management Companion &bull; <a href="terms-of-use.html">Terms of Use</a> &bull; Last updated: January 2026</div>
<button class="scroll-top" aria-label="Scroll to top" id="scrollTop" title="Back to top">&uarr;</button>
<script>
var sb=document.getElementById('scrollTop');window.addEventListener('scroll',function(){sb.classList.toggle('visible',window.scrollY>400)});sb.addEventListener('click',function(){window.scrollTo({top:0,behavior:'smooth'})});
</script>
</body></html>